Abstract 942P
Background
Immune checkpoint inhibitors (ICI) and platinum-based chemotherapy are the standard treatments of R/M SCCHN patients (pts). After progression on these therapies, there is a lack of data and no standard of care exists.
Methods
This is a multicentric retrospective study (3 French and 3 Swiss centers). We analyzed the efficacy and safety of paclitaxel alone (P) or in combination with the epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab (PC) beyond ICI progression in platinum-refractory and taxane naïve R/M SCCHN pts treated from January 2016 to August 2022. Primary endpoint was objective response rate (ORR) according to RECIST 1.1 criteria.
Results
We included 152 pts treated with P (69 pts, 45%) or PC (83 pts, 55%): 73% were males, 81% smokers. Median age was 67 (24-86). The ORR was 45% in the total population (TP), 22.4% in P group and 63.5% in PC group (p<0.001). The disease control rate (DCR) was 68.5% in the TP, 56.7% in P group and 78.1% in PC group (p=0.007). The median overall survival was 8.0 months (m) [95% CI: 7.0-9.4] in the TP, 6.9 m [95% CI: 5.5-8.2] in the P group and 9.4 m [95% CI: 8.0-11.8] in the PC group (p=0.02). The median progression free survival was 4.0 m [95% CI: 3.3-4.7] in the TP, 2.8 m [95% CI: 2.5-3.7] in the P group and 4.9 m [95% CI: 4.3-5.7] in the PC group (p<0.001). The rate of G3/G4 adverse event (AE) was 18.8% in P group and 21.7% in PC group. One patient died of septic shock in PC group. The most common G3/G4 AE were neuropathy (8.6%) in P group and acneiform rash (10%) in PC group. Table: 942P
Response Rate according to type of treatment CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; NE: Not evaluable
Total population N=152 | Paclitaxel N=69 | Paclitaxel-Cetuximab N=83 | |
CR | 4 (2.7%) | 1 (1.5%) | 3 (3.7%) |
PR | 63 (42.3%) | 14 (20.9%) | 49 (59.8 %) |
SD | 35 (23.5%) | 23 (34.3%) | 12 (14.6%) |
PD | 47 (31.5%) | 29 (43.3%) | 18 (22%) |
NE | 3 | 2 | 1 |
Conclusions
Taxane-based chemotherapy is highly active and well-tolerated after ICI failure in platinum-refractory R/M SCCHN pts. Our results suggest a potential additional benefit of cetuximab combined with paclitaxel in this population and deserves further investigation in prospective randomized clinical trials.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
CHUV - Centre Hospitalier Universitaire Vaudois.
Funding
Has not received any funding.
Disclosure
E. Auclin: Financial Interests, Personal and Institutional, Advisory Board: Amgen, Sanofi. C. Gervais: Financial Interests, Personal, Invited Speaker: MSD, mundipharma, astellas, janssen. V.G. Espeli: Financial Interests, Institutional, Speaker, Consultant, Advisor: Merck-Serono, Merck Sharp&Dohme; Non-Financial Interests, Personal and Institutional, Other, Travel, Accommodations, Expenses: Sanofi. S.I. Rothschild: Financial Interests, Institutional, Speaker, Consultant, Advisor: AstraZeneca, Roche Pharma AG, Bristol Myers Squibb, Boehringer Ingelheim, MSD Oncology, Novartis, Amgen, Eli Lilly, Eisai, Merck Serono, Pfizer, Takeda, Bayer, Janssen Oncology, Otsuka, PharmaMar, Sanofi/Aventis; Financial Interests, Institutional, Research Funding: AbbVie, Bristol Myers Squibb, AstraZeneca, Boehringer Ingelheim, Merck Serono, Roche Pharma AG. C. Even: Financial Interests, Personal, Advisory Board: BMS, MSD, Innate Pharma, Merck Serono; Financial Interests, Institutional, Advisory Board: F Star Therapeutics, Novartis, Elevar; Financial Interests, Institutional, Local PI: BMS, AstraZeneca, ISA pharmaceutics, MSD, Debiopharma, Ayala, Gilead; Financial Interests, Institutional, Coordinating PI: BMS, Novartis, sanofi. V. Cristina: Financial Interests, Institutional, Speaker, Consultant, Advisor: Merck Sharp&Dohme, Merck-Serono; Financial Interests, Institutional, Invited Speaker: Eisai; Financial Interests, Institutional, Advisory Board: Eli Lilly, Servier; Financial Interests, Institutional, Local PI: Merck Sharp&Dohme, Merck-Serono, MaxiVAX. All other authors have declared no conflicts of interest.
Resources from the same session
941P - Risk factors for progressive disease after immune checkpoint inhibitors (ICIs) in advanced head and neck squamous cell carcinoma (HNSCC): Who might not be candidate for ICI?
Presenter: Seo Yoon Jang
Session: Poster session 12
944TiP - Randomized phase II study of immune stimulation with pembrolizumab and radiotherapy of recurrent and/or metastatic head and neck squamous cell carcinoma : The IMPORTANCE trial
Presenter: Bálint Tamaskovics
Session: Poster session 12
1089P - Adjuvant nivolumab (NIVO) vs ipilimumab (IPI) in resected stage III/IV melanoma: 7-y results from CheckMate 238
Presenter: Paolo Ascierto
Session: Poster session 12
1090P - Outcome impact of time from complete resection to start of adjuvant immunotherapy in stage III-IV melanoma patients
Presenter: Sergio Martinez Recio
Session: Poster session 12
1092P - Adjuvant treatment with anti-PD-1 in acral melanoma patients: A nationwide study
Presenter: Manja Bloem
Session: Poster session 12
1093P - Neoadjuvant (NeoAd) intratumoral (IT) TAVO-EP (plasmid IL-12 electro gene transfer) in combination with nivolumab (NIVO) for patients (pts) with operable locoregionally advanced melanoma
Presenter: Ahmad Tarhini
Session: Poster session 12
1094P - Relapse free survival (RFS) at 3 years by pathological (path) response to neoadjuvant systemic treatment (NST) in patients (pts) with surgically resectable, high-risk melanoma
Presenter: Elizabeth Burton
Session: Poster session 12
1095P - Associations between baseline biomarkers and 3-year survival in the PRADO trial testing neoadjuvant ipilimumab and nivolumab in stage III melanoma
Presenter: Irene Reijers
Session: Poster session 12